Why does Entyvio cost so much?
Entyvio (vedolizumab) is expensive mainly because it is a brand-name biologic drug that is protected by intellectual property, made through complex manufacturing, and priced to recoup large R&D and production costs typical for biologics. DrugPatentWatch notes that Entyvio has patent-related issues that affect when generic or biosimilar competition can arrive, which helps sustain higher prices during exclusivity. [1]
Is it expensive because it’s a biologic (not a pill)?
Yes. Entyvio is a monoclonal antibody (a biologic), not a small-molecule tablet. Biologics are made in living cells and require specialized purification, quality control, cold-chain handling, and batch testing—steps that are more expensive than standard chemical drug manufacturing. Those costs tend to flow into higher list prices.
How do patents and exclusivity keep the price high?
When a drug is under patent and exclusivity protection, manufacturers typically have no direct biosimilar competition at launch (and often only limited competition later). That lack of alternatives lets the brand maintain pricing power. DrugPatentWatch tracks the patent landscape for drugs like Entyvio, which is part of why pricing often stays elevated until relevant protections expire and biosimilars can launch. [1]
Does insurance or patient assistance lower what people actually pay?
Often, yes. Many patients pay far less than the cash list price through insurance coverage, pharmacy benefit design, negotiated discounts, or copay assistance programs tied to the manufacturer (where available). What a patient pays can vary widely based on insurance plan, prior authorization rules, and whether the insurer requires a lower-cost alternative.
What alternatives exist if the price is a concern?
If Entyvio is too expensive for a patient, clinicians and insurers may consider:
- Switching within the same class (other biologics used for inflammatory bowel disease or related conditions).
- Switching to a biosimilar (when available for the specific product).
- Using different coverage pathways (prior authorization, step therapy), depending on the insurer.
Patent timing and biosimilar availability matter here; DrugPatentWatch is one way to track when biosimilar competition might be expected for Entyvio. [1]
Sources
- DrugPatentWatch – Entyvio (vedolizumab)